Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $11.24 in the prior trading day, Olema Pharmaceuticals Inc (NASDAQ: OLMA) closed at $10.85, down -3.47%. In other words, the price has decreased by -$3.47 from its previous closing price. On the day, 0.61 million shares were traded. OLMA stock price reached its highest trading level at $11.02 during the session, while it also had its lowest trading level at $10.585.
Ratios:
Our goal is to gain a better understanding of OLMA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.33 and its Current Ratio is at 12.33. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on April 02, 2024, initiated with a Buy rating and assigned the stock a target price of $24.
On January 30, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $20.
On July 21, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $21.Oppenheimer initiated its Outperform rating on July 21, 2023, with a $21 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 06 ’24 when Harmon Cyrus sold 5,000 shares for $10.92 per share. The transaction valued at 54,600 led to the insider holds 806,283 shares of the business.
Harmon Cyrus sold 15,000 shares of OLMA for $142,650 on Apr 30 ’24. The Director now owns 811,283 shares after completing the transaction at $9.51 per share. On Mar 28 ’24, another insider, Harmon Cyrus, who serves as the Director of the company, sold 20,000 shares for $10.97 each. As a result, the insider received 219,400 and left with 826,283 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 606881728 and an Enterprise Value of 369091680.
Stock Price History:
The Beta on a monthly basis for OLMA is 2.12, which has changed by 0.6927711 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, OLMA has reached a high of $17.79, while it has fallen to a 52-week low of $5.02. The 50-Day Moving Average of the stock is -5.11%, while the 200-Day Moving Average is calculated to be -10.99%.
Shares Statistics:
The stock has traded on average 805.69K shares per day over the past 3-months and 703630 shares per day over the last 10 days, according to various share statistics. A total of 54.99M shares are outstanding, with a floating share count of 48.61M. Insiders hold about 13.10% of the company’s shares, while institutions hold 86.60% stake in the company. Shares short for OLMA as of 1713139200 were 8974804 with a Short Ratio of 11.14, compared to 1710460800 on 5058335. Therefore, it implies a Short% of Shares Outstanding of 8974804 and a Short% of Float of 21.490000000000002.
Earnings Estimates
The performance of Olema Pharmaceuticals Inc (OLMA) in the stock market is under the watchful eye of 7.0 analysts actively contributing to its current rating.On average, analysts expect EPS of -$0.55 for the current quarter, with a high estimate of -$0.51 and a low estimate of -$0.58, while EPS last year was -$0.7. The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.55 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$2.28 and -$2.56 for the fiscal current year, implying an average EPS of -$2.4. EPS for the following year is -$2.66, with 8.0 analysts recommending between -$2.41 and -$3.0.
